Ahmad Kahf
Cardiovascular Disease · Haledon, NJNPI 1922069517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,158 and has fallen 96.1% since, to $45 in 2024.
Across 321 payments — averaging $12.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$789
- Teva Pharmaceuticals USA, Inc.$769
- Lilly USA, LLC$265
- Novartis$219
- Amgen$218
- GSK$192
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,925100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 92 | $789 |
| Teva Pharmaceuticals USA, Inc. | 66 | $769 |
| Lilly USA, LLC | 20 | $265 |
| Novartis | 15 | $219 |
| Amgen | 15 | $218 |
| GSK | 14 | $192 |
| Sunovion Pharmaceuticals Inc. | 10 | $134 |
| AbbVie | 9 | $133 |
| Bayer | 8 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $96 |
| Merck | 6 | $95 |
| Ironwood Pharmaceuticals, Inc | 6 | $88 |
| Dexcom, Inc. | 6 | $79 |
| Pfizer | 5 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Astellas Pharma US Inc | 4 | $56 |
| Amarin Pharma, Inc. | 4 | $54 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| G Medical Diagnostic Services, Inc. | 2 | $43 |
| Vivus LLC | 3 | $41 |
| Medtronic | 2 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Mylan Specialty L.p. | 1 | $19 |
| Lundbeck LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$3,925 in reported general payments places this provider in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 34 | $19,106 |
| EliquisApixaban | 40 | $15,062 |
| LinzessLinaclotide | 16 | $13,741 |
| Formoterol Fumarate | 12 | $12,896 |
| FarxigaDapagliflozin Propanediol | 22 | $9,325 |
| Memantine Hcl | 35 | $9,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $9,032 |
| EntrestoSacubitril/Valsartan | 15 | $7,177 |
| Divalproex Sodium | 49 | $4,852 |
| Budesonide | 25 | $4,260 |
| Enoxaparin Sodium | 44 | $3,919 |
| Diclofenac Sodium | 22 | $3,866 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $3,495 |
| Gabapentin | 34 | $3,270 |
| Scopolamine | 14 | $2,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $95 | $19,10634 claims |
| PfizerEliquis | $73 | $15,06240 claims |
| AbbVieLinzess | $133 | $13,74116 claims |
| AstraZenecaFarxiga | $29 | $9,32522 claims |
| GSKTrelegy Ellipta | $192 | $9,03218 claims |
| NovartisEntresto | $219 | $7,17715 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $769 | $33315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Haledon
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.